Castle Biosciences (CSTL) Elevates 2026 Revenue Forecast as Q2 Core Test Volume Surges

Key numbers and what they imply

Castle Biosciences announced Q2 2026 revenues of $103.5 million versus $86.2 million in the second quarter of 2025. The delta reflects a 32% increase in total test reports for its core revenue drivers, specifically DecisionDx-Melanoma and TissueCypher, underscoring stronger clinician adoption and payer alignment for precision-guided cancer care.

Management highlights the growth in DecisionDx-Melanoma and TissueCypher volumes, with quarterly test reports rising to:

• DecisionDx-Melanoma: 10,280 reports (Q2 2026) versus 9,981 (Q2 2025)
• TissueCypher: 14,988 reports (Q2 2026) versus 9,170 (Q2 2025)

On the guidance front, the company raised its revenue forecast for full-year 2026 to a range of $365-375 million from $345-355 million, signaling sustained momentum into the back half of the year. Management also indicated that it now expects positive Adjusted EBITDA for the third and fourth quarters, and for the full year 2026, a potential milestone that investors tend to view as a near-term earnings proxy.

What the company says, and what it might portend

In the release, CEO Derek Maetzold framed the quarter as a continuation of “momentum,” emphasizing the clinical value of Castle’s tests and the dedication of its team. The tone pairs optimistic guidance with a disciplined trajectory—shifting toward profitability measures that investors often treat as a more reliable proxy than headline revenue alone.

A notable ancillary point is the discussion of a real-world study tied to AdvanceAD-Tx, which the company frames as supportive evidence of how molecularly guided testing can steer systemic therapy toward pathway-concordant treatment. The study’s result—54.3% of patients on baseline systemic therapy initially on a non-concordant path, moving to 97.8% concordant after testing—is indirect evidence of demand for Castle’s tools to improve treatment alignment. While not a traditional earnings metric, such data bolster the strategic case for continued adoption and potential downstream payer and clinical-network benefits.

The absence of a reported GAAP EPS in this release means investors will look to upcoming filings for quarterly earnings per share figures and related EPS consensus estimates. Given the shift toward positive Adjusted EBITDA, the narrative suggests the path to EPS expansion could hinge on operating leverage from higher test volumes and any gross-margin improvements as the payer mix evolves.

Implications for Castle’s peers and the broader diagnostics space

The Q2 results reinforce a theme visible across precision oncology diagnostics: payer coverage dynamics and the ability to translate test adoption into more selective, effective therapy. As CSTL works through Medicare coverage nuances and the strategic discontinuation of older panels, the key question for sector peers is whether there is room for additional specialization buys—more tests that anchor treatment pathways and convert test reports into real-world clinical actions.

If Castle sustains its trajectory, a few plausible cross-impacts may emerge:

• Increased emphasis on core flagship tests as growth engines, with investors scrutinizing rollouts, payer approvals, and physician adoption rates.
• Potential margin expansion as fixed costs dilute with higher volumes, aiding the path to positive EBITDA and, eventually, per-share profitability (EPS).
• Emerging studies and real-world evidence may become material catalysts for broader revenue forecast upgrades across the specialty diagnostics ecosystem.

Analysts will be watching not just the top-line beat or miss, but also the cadence of EBITDA non-GAAP metrics, test-volume growth by franchise, and the resilience of revenue in a healthcare environment shaped by payer policy shifts and clinical practice evolution.

Bottom line for investors

Castle Biosciences’ Q2 2026 narrative blends a solid revenue base with a clear lift in core test volumes and a raised full-year revenue forecast. The company’s ability to sustain positive Adjusted EBITDA into Q3 and Q4 could serve as a catalyst for EPS growth in 2027, provided operating leverage holds and test volumes stay buoyant. For now, the “story” rests on decisions made by clinicians and payers, rather than headline quarterly earnings surprises. In other words, the castle’s drawbridge is up, the moat looks healthy, and management is signaling the drawbridge won’t be lowered anytime soon—assuming the revenue forecast stays in reach and EBITDA remains in the black.

Notes

Ticker: CSTL; EPS: not disclosed in this release; earnings surprise: not reported; EPS consensus: to be determined; revenue forecast: raised to $365-375 million for 2026. Core revenue drivers: DecisionDx-Melanoma, TissueCypher; additional tests include DecisionDx-SCC and historical links to Medicare coverage changes and the discontinuation of IDgenetix in 2025.